Business Wire - CyDex Announces Captisol Technology Used in Injection Formulation of Veterinary Anti-Emetic Cerenia® Recently Approved for Marketing in Europe
LENEXA, Kan. — CyDex, Inc., a specialty pharmaceutical company developing improved products through innovative drug delivery, today announced that a subcutaneous injection formulation of the veterinary anti-emetic medication Cerenia([R])(maropitant) from Pfizer Limited contains CyDex’s Captisol([R])-enabling technology.
On September 29, 2006, the European Medicines Agency approved both the subcutaneous injection and tablet formulations of Pfizer’s Cerenia for marketing throughout the European Union. Cerenia for Injection is used in dogs to prevent vomiting and treat vomiting such as that caused by chemotherapy.
Most Popular
Network Security Checklist
Keys To Teamwork / Teambuilding Success
Request For Interview
Public Speaking: 7 Secrets Of Great Public Speakers
Managers Can - and Should - Learn How to Manage
Cerenia for Injection is the fourth drug formulation utilizing Captisol to receive marketing approval. The other three Captisol-enabled drugs currently are commercially available. These include Geodon IM and Vfend IV, marketed globally by Pfizer Inc., and ABILIFY Injection marketed in the United States by Bristol-Myers Squibb and Otsuka Pharmaceutical Co.
CyDex’s patented Captisol technology improves water solubility, bioavailability and complexation characteristics of insoluble and/or unstable drugs. In addition to injectable products, the CyDex pipeline of licensed and proprietary Captisol-enabled formulations targets a range of market segments including oral solutions and capsules, ophthalmic solutions, oral solids and inhalation.
“Pfizer’s launch of Cerenia for Injection further illustrates the power of Captisol as an agent for improving aqueous solubility and thus enabling new dosage forms that can both broaden and lengthen the sales revenue stream for new drugs,” said CyDex Chief Executive Officer John M. Seibert. “CyDex’s pharmaceutical industry partners recognize that Captisol can serve as a valuable tool for drug lifecycle management, and we are working toward additional product launches by an expanding roster of partners in future years.”
About CyDex, Inc.
CyDex is a specialty pharmaceutical company developing proprietary products and licensing its Captisol([R])-enabling technology. CyDex is bringing important new medications to patients by developing its own pipeline of proprietary products with advanced drug delivery solutions, and by partnering with the world’s leading pharmaceutical and biotechnology companies. In addition to Cerenia([R]) for Injection, the commercially available pharmaceuticals enabled by Captisol include Geodon IM and Vfend IV, marketed globally by Pfizer Inc., and ABILIFY Injection marketed in the United States by Bristol-Myers Squibb and Otsuka Pharmaceutical Co., Ltd., CyDex has development agreements with Allergan, Inc.; Bristol-Myers Squibb; Daiichi Asubio Pharma Co., Ltd., of Japan; Merck & Co., Inc.; Mitsubishi Corporation, of Japan; OSI Pharmaceuticals, Inc.; PTC Pharma AG, of Switzerland; TargeGen, Inc.; Taisho Pharmaceuticals of Japan and Teva Pharmaceutical Industries Ltd., of Israel. CyDex also has clinical use agreements with major pharma and biotech companies. CyDex is a privately held company located in suburban Kansas City. To learn more about the company, please visit www.cydexinc.com.
Captisol and Captisol-enabled are registered trademarks of CyDex, Inc. Cerenia, Geodon IM and Vfend IV are registered trademarks of Pfizer Inc. ABILIFY is a registered trademark of Otsuka Pharmaceutical Co., Ltd.
COPYRIGHT 2007 Business Wire
COPYRIGHT 2008 Gale, Cengage Learning
